INDICATIONS     CONTRA-INDICATIONS     DOSAGE     SIDE-EFFECTS     PREGNANCY     OVERDOSE     IDENTIFICATION     PATIENT INFORMATION

Logo TYPHOID and TETANUS VACCINE

TYPHOID AND TETANUS VACCINE
Typhoid/Tet. Vac
PROPRIETARY NAME:
TYPHOID and TETANUS VACCINE

DESCRIPTIVE NAME:
A Bacterial
Typhoid and Tetanus Vaccine

REGISTRATION NUMBER:
T531 (Act 101/1965)

PHARMACOLOGICAL CLASSIFICATION:
A30.1 Antigens

SCHEDULING STATUS:
S2

COMPOSITION:
Each 0,5 mL contains 500 million of Formalin inactivated Salmonella Typhi and 10 Lf of Purified Tetanus Toxoid in Saline Solution, with 0,5% Phenol as preservative.

IDENTIFICATION:
A pale milky translucent suspension with a slight odour due to the preservative.

PHARMACOLOGICAL ACTION:
Induces in the recipient a specific active immunity to Typhoid Fever and Tetanus.

INDICATIONS:
For primary immunisation against Typhoid Fever and Tetanus.

CONTRA-INDICATIONS:
Not recommended for patients with acute infections or chronic debilitating illness, or for children less than 1 year old. Should be used with great caution if there has been a history of allergy to previous vaccination.

DOSAGE AND DIRECTIONS FOR USE:
For primary immunisation of adults, 2 doses of 0,.5 mL are given by subcutaneous injection 4 to 6 weeks apart. To provide adequate protection, a third dose should be given 6 months later. A single dose of Tetanus vaccine may be given as a reinforcing dose after two years, if indicated.
Sterilise the rubber closure with tincture of iodine and shake vial vigorously before use.

SIDE EFFECTS AND SPECIAL PRECAUTIONS:
Enquiry regarding previous hypersensitivity should precede the administration of a vaccine, and measures to treat reactions should be immediately available. Anaphylactic reactions, which are rare, should be treated with adrenaline, possibly in association with antihistamine and corticosteroid therapy.

Reactions following administration may include anorexia, fever, vomiting, and malaise. May cause transient local and general reactions for which symptomatic treatment should be given. Local reactions are more likely to occur after reinforcing or booster doses.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
No known symptoms.

PRESENTATION:
Single dose ampoules containing 0,5 mL.
Multidose 10 mL vials (20 doses) packed singly.
Multidose 10 mL vials packed 10 x 10 mL.

STORAGE INSTRUCTIONS:
Store at 2° C to 10° C. DO NOT FREEZE. Protect from light.

NAME AND BUSINESS ADDRESS OF APPLICANT:
The South African Institute for Medical Research.
Rietfontein, Edenvale, Transvaal.
P.O. Box 28999, Sandringham, 2131

DATE OF PUBLICATION OF THIS PACKAGE INSERT:
June 1990

123-694

SAEPI HOME PAGE      TRADE NAME INDEX      GENERIC NAME INDEX      FEEDBACK
Information presented by Malahyde Information Systems © Copyright 1996,1997,1998